GlassScriptPhysician profile
Coleen Simon
NPI 1730542721
$2,970.78
in general payments reported to CMS, 2019-2025
14 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $670 · 2023: $786 · 2024: $549 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,717.62 | 2021-2025 | Aveir, Merlin@Home, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $634.90 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $244.21 | 2021-2025 | Watchman, Farapulse, Watchman Flx |
| Pfizer INC. | $65.96 | 2022-2025 | |
| Chiesi USA, INC. | $58.77 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.34 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $43.75 | 2022-2025 | Lokelma |
| Amgen INC. | $36.57 | 2023-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $33.74 | 2021-2023 | Xarelto |
| Abiomed | $19.66 | 2024 | Impella |
| Bridgebio Pharma, INC. | $19.53 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $19.51 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.67 | 2023 | Inpefa |
| Medtronic, INC. | $13.55 | 2025 | Corevalve Evolut R |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coleen Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.